García-Martínez, José ManuelChocarro-Calvo, AnaMartínez-Useros, JavierFernández-Aceñero, María JesúsFiuza, M. CarmenCáceres-Rentero, JoseDe la Vieja, AntonioBarbáchano, AntonioMuñoz, AlbertoLarriba, María JesúsGarcía-Jiménez, Custodia2024-06-282024-06-282023-08-02García-Martínez José Manuel, Chocarro-Calvo Ana, Martínez-Useros Javier, Fernández-Aceñero María Jesús, Fiuza M. Carmen, Cáceres-Rentero Jose, De la Vieja Antonio, Barbáchano Antonio, Muñoz Alberto, Larriba María Jesús, García-Jiménez Custodia (2023) Vitamin D induces SIRT1 activation through K610 deacetylation in colon cancer eLife 12:RP86913 https://doi.org/10.7554/eLife.86913.22050-084Xhttps://hdl.handle.net/10115/35623Posttranslational modifications of epigenetic modifiers provide a flexible and timely mechanism for rapid adaptations to the dynamic environment of cancer cells. SIRT1 is an NAD+-dependent epigenetic modifier whose activity is classically associated with healthy aging and longevity, but its function in cancer is not well understood. Here, we reveal that 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3, calcitriol), the active metabolite of vitamin D (VD), promotes SIRT1 activation through auto-deacetylation in human colon carcinoma cells, and identify lysine 610 as an essential driver of SIRT1 activity. Remarkably, our data show that the post-translational control of SIRT1 activity mediates the antiproliferative action of 1,25(OH)2D3. This effect is reproduced by the SIRT1 activator SRT1720, suggesting that SIRT1 activators may offer new therapeutic possibilities for colon cancer patients who are VD deficient or unresponsive. Moreover, this might be extrapolated to inflammation and other VD deficiency-associated and highly prevalent diseases in which SIRT1 plays a prominent role.engAttribution 4.0 Internacionalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/article10.7554/eLife.86913.2info:eu-repo/semantics/openAccess